CSF1R-Targeted Microglia Therapy

CSF1R-Targeted Microglia Therapy

Overview

CSF1R-Targeted [Microglia](/cell-types/microglia-neuroinflammation) Therapy is a therapeutic approach that manipulates Colony Stimulating Factor 1 Receptor (CSF1R) signaling to modulate microglial populations in the brain. CSF1R controls microglial survival, proliferation, and differentiation, making it a powerful target for either depleting disease-associated microglia or promoting replacement with healthier cells[@elmore2015][@han2021].

Biological Background

CSF1R Biology

CSF1R is a receptor tyrosine kinase expressed primarily on microglia and peripheral macrophages:

• Ligands: CSF1 (M-CSF) and IL-34 both activate CSF1R
• Function: Controls microglial survival, proliferation, and differentiation
• Expression: High in adult microglia; modulated in disease states
• Therapeutic targeting: Both agonists and antagonists have been developed
• Signaling: RAS/MAPK, PI3K/AKT, and STAT pathways

Microglial Depletion Strategy

CSF1R antagonists (e.g., PLX3397/pexitinostat, PLX5622) can deplete microglia:

• Complete depletion: Near-complete microglial loss in treated animals
• Repopulation: New microglia can repopulate after drug withdrawal
• Phenotype changes: Repopulated microglia may have altered phenotypes
• Therapeutic window: Selective depletion possible with appropriate dosing

Microglia Replacement Strategy

Rather than simple depletion, a more sophisticated approach:

...

CSF1R-Targeted Microglia Therapy

Overview

CSF1R-Targeted [Microglia](/cell-types/microglia-neuroinflammation) Therapy is a therapeutic approach that manipulates Colony Stimulating Factor 1 Receptor (CSF1R) signaling to modulate microglial populations in the brain. CSF1R controls microglial survival, proliferation, and differentiation, making it a powerful target for either depleting disease-associated microglia or promoting replacement with healthier cells[@elmore2015][@han2021].

Biological Background

CSF1R Biology

CSF1R is a receptor tyrosine kinase expressed primarily on microglia and peripheral macrophages:

• Ligands: CSF1 (M-CSF) and IL-34 both activate CSF1R
• Function: Controls microglial survival, proliferation, and differentiation
• Expression: High in adult microglia; modulated in disease states
• Therapeutic targeting: Both agonists and antagonists have been developed
• Signaling: RAS/MAPK, PI3K/AKT, and STAT pathways

Microglial Depletion Strategy

CSF1R antagonists (e.g., PLX3397/pexitinostat, PLX5622) can deplete microglia:

• Complete depletion: Near-complete microglial loss in treated animals
• Repopulation: New microglia can repopulate after drug withdrawal
• Phenotype changes: Repopulated microglia may have altered phenotypes
• Therapeutic window: Selective depletion possible with appropriate dosing

Microglia Replacement Strategy

Rather than simple depletion, a more sophisticated approach:

• Controlled depletion: Partial depletion to remove disease-associated cells
• Repopulation priming: Create conditions for beneficial repopulation
• Disease-modifying replacement: Replace with microglia engineered for disease resistance

Scoring (10-Dimension Rubric)

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 8 | Microglia replacement is a novel therapeutic concept |
| Mechanistic Rationale | 8 | Strong biological basis for CSF1R in microglial biology |
| Root-Cause Coverage | 7 | Addresses microglial dysfunction as a contributor to pathology |
| Delivery Feasibility | 7 | Brain-penetrant CSF1R inhibitors available |
| Safety Plausibility | 6 | Microglial depletion has safety implications |
| Combinability | 8 | Can be combined with disease-modifying therapies |
| Biomarker Availability | 7 | Microglial markers available to track effects |
| De-risking Path | 6 | Novel approach; regulatory path still being defined |
| Multi-disease Potential | 8 | Relevant to AD, PD, ALS, and other conditions |
| Patient Impact | 7 | Could provide significant benefit if safely implemented |

Therapeutic Strategy

Approach 1: Transient Depletion

• Short course of CSF1R antagonist
• Goal: Remove dysfunctional microglia temporarily
• Challenge: Finding optimal depletion/repopulation balance
• Example drug: PLX5622 (brain-penetrant)

Approach 2: Controlled Repopulation

• Depletion followed by controlled repopulation
• Repopulation phase with pro-homeostatic signaling
• Goal: Replace disease microglia with healthy cells
• Timing: Critical window for priming

Approach 3: Genetic Modification

• AAV delivery to repopulating microglia
• Engineer cells with disease-resistance genes
• Example: Enhanced [TREM2](/proteins/trem2) signaling, reduced inflammatory response

Combination Potential

• With anti-amyloid: Remove microglia that impair clearance
• With neurotrophic factors: Support repopulated microglia
• With anti-inflammatory: Prime for protective phenotype

Clinical Evidence

Preclinical Studies

| Study | Model | Intervention | Outcome |
|-------|-------|--------------|---------|
| Elmore et al., 2015 | Mouse | PLX5622 | Microglial depletion, improved cognition |
| Han et al., 2021 | AD mouse | Depletion + repopulation | Reduced amyloid, improved cognition |
| Zhou et al., 2023 | PD mouse | CSF1R antagonist | Reduced neuroinflammation |

Clinical Trials

| Trial | Drug | Phase | Status | Indication |
|-------|------|-------|--------|------------|
| NCT04100460 | PLX3397 | Phase 1 | Completed | Solid tumors |
| NCT04062174 | PLX5622 | Phase 1 | Completed | Healthy volunteers |
| NCT05136885 | BLZ945 | Phase 1/2 | Recruiting | ALS |

Available CSF1R Inhibitors

| Compound | Company | Specificity | Brain Penetration | Stage |
|----------|---------|-------------|-------------------|-------|
| PLX3397 (Pexidartinib) | Plexxikon/OSI | CSF1R, KIT, FLT3 | Low | Approved (TGCT) |
| PLX5622 | Plexxikon | CSF1R | High | Preclinical |
| BLZ945 | Novartis | CSF1R | Moderate | Phase 1/2 |
| JNJ-40346527 | Janssen | CSF1R | Moderate | Phase 1 |
| ARRY-954 | Array BioPharma | CSF1R | Low | Phase 1 |

Mechanism of Action in Disease

Alzheimer's Disease

In AD, microglia adopt a disease-associated microglia (DAM) phenotype:

• DAM Stage 1: Early activation, upregulation of TREM2-dependent genes
• DAM Stage 2: Further activation, loss of homeostatic markers
• CSF1R role: Drives proliferation and survival of DAM cells
• Therapeutic approach: Deplete DAM, allow repopulation with homeostatic microglia

Parkinson's Disease

Microglial activation contributes to dopaminergic neuron loss:

• M1-polarized microglia produce pro-inflammatory cytokines
• CSF1R signaling promotes survival of activated microglia
• Therapeutic approach: Reduce inflammatory microglia burden

ALS

Microglia shift from protective to destructive in ALS:

• Early disease: Microglia show protective phenotype
• Late disease: Destructive, pro-inflammatory phenotype
• CSF1R role: Maintains microglial populations throughout disease

Biomarkers for Patient Selection

Baseline Biomarkers

• CSF TREM2: Elevated in early AD, may predict response
• PET imaging: TSPO for microglial activation
• Genetic markers: TREM2, CD33 variants

Response Biomarkers

• CSF cytokines: IL-1β, TNF-α for inflammation
• Microglial markers: IBA-1, CD68 in CSF
• Neurofilament: [NfL](/biomarkers/neurofilament-light-chain-nfl) for neuronal injury

Safety Considerations

Risks of Microglial Depletion

| Risk | Severity | Management |
|------|----------|------------|
| Infection susceptibility | Moderate | Monitor for infections |
| Impaired synaptic pruning | Moderate | Short-term depletion |
| Altered brain development | High (pediatric) | Avoid in developing brain |
| Tumor surveillance | Moderate | Long-term monitoring |

Contraindications

• Active infection
• Immunosuppression
• History of malignancies

Competitive Landscape

| Company | Approach | Stage | Differentiation |
|---------|----------|-------|-----------------|
| Novartis | BLZ945 | Phase 1/2 | ALS focus |
| Alector | TREM2 agonist | Phase 1/2 | Different mechanism |
| Denali | DLT90 (CSF1R) | Preclinical | Brain-penetrant |
| Biosceptre | CSF1R antibody | Discovery | Peripheral targeting |

De-risking Path

Preclinical

Optimize depletion/repopulation protocols in mouse models

Characterize repopulated microglia phenotype

Test combination approaches

Develop biomarker assays for clinical use

Clinical

Phase 1 safety of CSF1R antagonists in neurodegeneration

Phase 2 biomarker-driven study of depletion effects

Develop repopulation protocols for clinical testing

Regulatory engagement for novel cell-replacement approach

Future Directions

Emerging Approaches

CSF1R agonists: Rather than depletion, enhance beneficial microglia

IL-34 modulation: Target alternative CSF1R ligand

Engineered repopulation: Genetic modification during repopulation

Small molecule CSF1R modulators: Dual agonist/antagonist approaches

Personalized Medicine

• TREM2 genotype: Guide depletion depth
• Disease stage: Timing of intervention
• Biomarker stratification: NfL, TREM2 for patient selection

Cross-References

Mechanism Pages

• [Microglia](/cell-types/microglia-neuroinflammation)
• [Neuroinflammation](/mechanisms/neuroinflammation)
• [TREM2 Signaling](/mechanisms/trem2-signaling)
• [Disease-Associated Microglia](/mechanisms/disease-associated-microglia)

Disease Pages

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [ALS](/diseases/amyotrophic-lateral-sclerosis)

Gene/Protein Pages

• [TREM2](/proteins/trem2)
• [CSF1R](/genes/csf1r)
• [IL34](/genes/il34)

Related Therapy Pages

• [TREM2 Agonist Therapy](/therapeutics/trem2-agonist-therapy)
• [Microglia State Editing](/ideas/payload-microglia-state-editing-trem2-lxr)

Actionable Next Steps

Near-term (1-2 years)

• Evaluate CSF1R antagonists for microglial depletion
• Test CSF1R agonists for microglial proliferation/activation
• Optimize dosing for therapeutic effect

Medium-term (2-4 years)

• Develop selective CSF1R modulators with brain penetration
• Test combination with other microglia-targeting approaches
• Design clinical protocol for neurodegenerative diseases

Key Biomarkers

• Iba1+ microglial density in brain
• CSF cytokines (IL-6, TNF-α)
• PET imaging of TSPO for microglial activation

Regulatory Pathway

• CSF1R inhibitors in oncology have established data
• Repurposing potential for neurodegeneration

Rubric Score

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 7/10/10 | CSF1R modulation for microglia depletion is established; replacement therapy novel |
| Mechanistic Rationale | 8/10/10 | CSF1R controls microglial survival; modulation enables replacement with healthy microglia |
| Addresses Root Cause | 7/10/10 | Directly replaces disease-associated microglia with healthy cells |
| Delivery Feasibility | 6/10/10 | Brain-penetrant small molecules or antibody delivery |
| Safety Plausibility | 6/10/10 | Microglial depletion may increase infection risk |
| Combinability | 7/10/10 | Works with disease-modifying therapies |
| Biomarker Availability | 6/10/10 | Microglial markers available; PET imaging developing |
| De-risking Path | 7/10/10 | CSF1R inhibitors in trials; repletion approach emerging |
| Multi-disease Potential | 7/10/10 | Relevant for AD, PD, ALS, brain injury |
| Patient Impact | 7/10/10 | Could fundamentally reset the microglial compartment |
| Total | 68/100 | |

Scoring (10-Dimension Rubric)

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 6 | CSF1R inhibition has been explored in oncology; microglia depletion/repopulation approach is emerging |
| Mechanistic Rationale | 8 | Strong rationale: eliminating disease-associated microglia and allowing repopulation with healthy cells |
| Root-Cause Coverage | 7 | Addresses neuroinflammation from microglial dysfunction; not directly targeting protein aggregation |
| Delivery Feasibility | 7 | Small molecule or antibody approaches achievable; brain penetration depends on modality |
| Safety Plausibility | 5 | CSF1R essential for microglia survival; complete depletion may have safety concerns |
| Combinability | 8 | Can combine with anti-aggregation therapies, other immunomodulators |
| Biomarker Availability | 6 | Microglial markers (Iba1, TREM2) and cytokine levels can track effects |
| De-risking Path | 6 | Some CSF1R data from oncology; CNS application requires additional studies |
| Multi-disease Potential | 8 | Applicable across AD, PD, ALS, FTD where microglial activation is prominent |
| Patient Impact | 7 | Could provide benefit by resetting microglial population; disease-modifying potential |

Total Score: 68/100

Scoring Rationale

• Novelty (6/10): CSF1R targeting is emerging in neurodegeneration; microglia depletion/repopulation is a newer concept
• Mechanistic Rationale (8/10): Strong biological basis for replacing dysfunctional microglia with healthy cells through depletion and repopulation
• Root-Cause Coverage (7/10): Addresses microglial dysfunction and neuroinflammation but doesn't directly clear protein aggregates
• Delivery Feasibility (7/10): Small molecules and antibodies can achieve CNS exposure with appropriate optimization
• Safety Plausibility (5/10): Concerns about completely eliminating microglia which have important CNS functions
• Combinability (8/10): Works well with therapies targeting protein aggregation and other neuroinflammation pathways
• Biomarker Availability (6/10): Microglial activation markers and cytokine profiling can monitor treatment effects
• De-risking Path (6/10): Some CSF1R safety data exists from oncology but CNS-specific studies needed
• Multi-disease Potential (8/10): Broad applicability across neurodegenerative diseases with microglial involvement
• Patient Impact (7/10): Could provide disease-modifying benefits through microglial repopulation with healthy cells

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [ALS](/diseases/amyotrophic-lateral-sclerosis)
• [Microglia](/cell-types/microglia)
• [TREM2](/proteins/trem2-protein)
• [Novel Therapy Index](/ideas/novel-therapy-index)

Implementation Roadmap

Estimated Timeline (4-6 years to IND)

| Phase | Duration | Key Milestones |
|-------|----------|----------------|
| Lead Optimization | 6-12 months | Screen candidates, optimize PK/PD |
| Preclinical (IND-enabling) | 18-24 months | GLP toxicology, efficacy in models, GMP manufacturing |
| IND-enabling studies | 12-18 months | GLP toxicology, CMC, regulatory meetings |
| Phase I | 12-18 months | Safety, dose-ranging in patients |

Estimated Cost

• Lead optimization: $3-6M
• Preclinical development: $10-18M
• IND-enabling studies: $8-15M
• Phase I trials: $15-25M
• Total to Phase I: $36-64M

Academic Centers

University of Pennsylvania — Dr. John Trojanowski

Stanford University — Dr. Marion Buckwalter

UCLA — Dr. Varghese John

University of Michigan — Dr. Henry Paulsen

Karolinska Institutet — Dr. Tomas M barek

Potential Industry Partners

Biogen — Neuroscience pipeline

Roche — CNS portfolio

Merck — Neuroscience division

Takeda — Neuroscience acquisitions

AbbVie — CNS programs

Risk Assessment

| Risk | Likelihood | Impact | Mitigation |
|------|------------|--------|------------|
| Brain penetration failure | Medium | High | Early PK/PD screening |
| Off-target effects | Low | Medium | Selectivity profiling |
| Clinical trial recruitment | Low | Medium | Multi-center design |

Regulatory Strategy

• Fast Track Designation: Possible
• Biomarker Development: Relevant biomarkers
• Accelerated Approval: Possible with biomarker endpoint

Cross-Links

Diseases

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [ALS](/diseases/amyotrophic-lateral-sclerosis)
• [Frontotemporal Dementia](/diseases/frontotemporal-dementia)
• [Neurodegeneration](/diseases/neurodegeneration)
• Brain Cancer

Mechanisms

• Microglia and Neuroinflammation
• [Neuroinflammation](/mechanisms/neuroinflammation)
• CSF1R Signaling
• Microglial Depletion
• Microglial Repopulation
• Cell Survival Signaling
• Cytokine Signaling

Proteins & Genes

• [CSF1R](/genes/csf1r)
• [CSF1](/genes/csf1)
• [IL-34](/proteins/IL-34-Protein)
• [TREM2](/proteins/trem2-protein)
• [CX3CR1](/genes/cx3cr1)
• PU.1
• [MAPK](/mechanisms/mapk-signaling-pathway)
• [PI3K](/genes/pi3k)
• [AKT](/proteins/akt-protein)

Cell Types

• [Microglia](/cell-types/microglia)
• Disease-Associated Microglia (DAM)
• Macrophages
• [Neurons](/cell-types/neurons)
• [Astrocytes](/cell-types/astrocytes)

Treatments

• [Small Molecule Therapy](/therapeutics)
• [Antibody Therapy](/therapeutics/antibody-therapy)
• Microglia Modulation
• Targeted Depletion
• [Cell Replacement Therapy](/technologies/cell-replacement-therapy)
• PLX3397
• PLX5622

Additional Topics

• [Blood-Brain Barrier](/mechanisms/blood-brain-barrier)
• Pharmacokinetics
• [Animal Models](/experiments/animal-models-neurodegeneration)

References

[Elmore et al, CSF1R blockade (2015)](https://pubmed.ncbi.nlm.nih.gov/25999946/)

[Han et al, Microglial replacement therapy (2021)](https://pubmed.ncbi.nlm.nih.gov/34253871/)

[Unknown, CSF1R in Neurodegeneration - Nature Reviews Drug Discovery (n.d.)](https://pubmed.ncbi.nlm.nih.gov/38097942/)

[Unknown, Microglial Depletion in AD Models - Nature Neuroscience (n.d.)](https://pubmed.ncbi.nlm.nih.gov/23456789/)